Background. The survival of untreated non-small cell lung cancer (NSCLC), or the natural history, is an important perspective for patients considering resection for NSCLC. The National Cancer Database (NCDB) allows untreated NSCLC patients who were recommended to undergo surgical resection (ie, "operable") to be identified. The survival of untreated NSCLC patients in the NCDB was studied to determine the natural history of operable NSCLC.
Methods. The NCDB was queried for untreated clinical stage I to IIIA NSCLC patients diagnosed between 2003 and 2009. The natural history cohort was defined as patients who were recommended to undergo resection but went untreated.
Results. We identified 1,693 untreated patients with operable NSCLC. The median survival for clinical stage I, II, and IIIA was 16.6, 9.4, and 8.4 months, respectively. The 5-year Kaplan-Meier estimates of survival for clinical stage I, II, and IIIA NSCLC were 10.1%, 7.3%, and 4.9%, respectively. At each stage (I to IIIA), the survival of untreated operable NSCLC patients was superior to that of untreated NSCLC patients not recommended to undergo resection (nonoperable, p < 0.001). A multivariable Cox regression model identified increasing age, male gender, white (vs black) race, increasing comorbidity, squamous cell or large cell histology, and increasing stage as predictors of decreased survival.
Conclusions. The natural history of operable NSCLC, although poor, varies with clinical stage and is superior to that of nonoperable NSCLC.
(Ann Thorac Surg 2016;101:1850-5) Ó 2016 by The Society of Thoracic Surgeons L ung cancer is the leading cause of cancer deaths in the United States, with an estimated 158,040 deaths expected in 2015 [1] . For patients with locoregionally confined non-small cell lung cancer (NSCLC; clinical stage I to III) and adequate cardiopulmonary reserve to tolerate a major operation, surgical resection has been associated with the most encouraging long-term survival rates [2] [3] [4] [5] [6] . As a result, surgical resection is an important treatment consideration for clinical stage I to IIIA NSCLC patients.
As a part of the surgical consent process, patients must understand the potential benefits of resection. Survival rates from surgical series are often used as the justification for surgical resection; however, understanding the potential gains from resection without understanding the prognosis without treatment, or the natural history, is difficult for many patients. The proverbial "What if I don't do anything?" is a frequent question in a thoracic surgery clinic. Therefore, the natural history is an important perspective for patients attempting to balance surgical risk with the potential to benefit from surgical treatment.
The natural history of operable NSCLC has been difficult to study because most untreated patients in large data resources were not actually candidates for resection secondary to factors that could also influence their survival. More specifically, the untreated cohorts in many administrative databases (eg, Surveillance, Epidemiology, and End Results) largely comprised patients whose health-or tumor-related factors made them ineligible for resection (nonoperable). The same attributes that made them nonoperable would likely also threaten their overall survival [7, 8] . Therefore, exclusion of nonoperable patients is necessary to provide the best estimate for survival for untreated patients with operable cancer.
The National Cancer Database (NCDB) is a tumor registry that captures approximately 70% of newly diagnosed lung cancers in the United States [9] . In addition to containing rich sociodemographic data, the NCDB allows patients to be identified who were recommended to undergo resection, but refused. The cohort of patients that was recommended to undergo resection (operable) but went untreated was examined to determine the natural history of operable NSCLC. We examined the survival of untreated NSCLC patients in the NCDB who were recommended to undergo resection to determine the natural history of operable NSCLC.
Patients and Methods
This study was approved by the Yale School of Medicine Institutional Review Board. Patient consent was waived.
Data Source
The NCDB participant user file with data through 2012 was used in this study. The NCDB states, "The data used in the study are derived from a de-identified NCDB file. Stage IIIB patients were excluded from the study because surgical resection is often not considered as a first-line treatment in this stage group under current guidelines.
"Operable" vs "Nonoperable"
Patients were defined as being operable if:
A. they underwent surgical resection, B. their "Reason for No Surgery" field was coded as "Surgery of the primary site was not performed; it was recommended by the patient's physician, but was not performed as part of the first course of therapy.
No reason was noted in patient record," or C. their "Reason for No Surgery" field was coded as "Surgery of the primary site was not performed; it was recommended by the patient's physician, but this treatment was refused by the patient, the patient's family member, or the patient's guardian. The refusal was noted in patient record."
Patients were considered to be nonoperable if they did not undergo surgical resection and their "Reason for No Surgery" field was coded as "Surgery of the primary site was not recommended/performed because it was contraindicated due to patient risk factors (comorbid conditions, advanced age, etc.)." [10] Overall 137,841 patients with stage I to IIIA cancer met the inclusion criteria; of these, 56,109 (41%) underwent operations, 60,883 (44%) were medically treated, and 20,849 (15%) went untreated, including 1,693 who were documented to be operable and 2,296 who were documented to be nonoperable because of health-related reasons (most of the remaining untreated patients were coded as "Surgery of the primary site was not performed because it was not part of the planned first course treatment"; Table 1 ).
Data Elements
The full list of demographic, treatment, and cancer covariates available in the NCDB can be found online [11] . Median income level was determined based on 2000 United States Census data for the patient's zip code of origin. Patient comorbidities are represented with the use of a modified Charlson-Deyo score that combines 15 comorbid conditions into a score with 3 levels (0, 1, and 2þ) in order of increasing comorbid status [12] .
Statistical Analysis
Comparisons between the operable and nonoperable cohorts were made using c 2 tests for categoric variables and t tests for continuous variables. The Kaplan-Meier method was used to calculate stage-specific median and 5-year survival for untreated operable and nonoperable patients. The primary end point was date of death or last contact measured from the date of diagnosis. Comparisons across strata were made using the log-rank test.
To characterize specific risk factors for poor survival, a Cox proportional hazards model was developed to predict survival in the 1,693 operable patients who went untreated. The proportional hazards assumption was assessed using graphic methods (log-log plots and Kaplan-Meier curves) [13] . The variables considered included patient age, sex, race, Charlson-Deyo comorbidity score, median income, tumor site, tumor laterality, tumor histology, tumor grade, clinical stage, facility type and location, year of diagnosis, and primary insurance payer. Cox models were refined by backwards elimination with a p value of 0.05 set as the threshold for inclusion in the model. Final models are reported as hazard ratios with 95% confidence intervals, as well as p values.
The p value for statistical significance was set at 0.05. Missing data were not input, but were coded as "missing" in an attempt to identify any disproportionality in the missing subset. All analyses were performed using SAS 9.4 software (SAS Institute Inc, Cary, NC).
Results

Patients
From 2003 to 2009, the cohort of untreated NSCLC patients in the NCDB included 1,693 operable and 2,296 nonoperable patients (Table 2) . Nonoperable patients were older, were white, had more comorbidities, had higher incomes, had higher stage disease, and had Medicare insurance.
Natural History of Operable NSCLC Patients
The Kaplan-Meier survival curves for operable, untreated NSCLC for clinical stages I to IIIA are shown in Figure 1 . For reference, the survival of operable patients who underwent surgical resection are also shown for each stage. For operable patients who went untreated, the median survival was 16.6, 9.4, and 8.4 months for clinical stage I, II, and, IIIA, respectively. The 5-year overall survival was 10.1%, 7.3%, and 4.9% for clinical stage I, II, and IIIA, respectively. To better evaluate the prognostic importance of "operability" on the natural history of NSCLC, the survival of untreated patients defined as operable was compared with those defined as being nonoperable secondary to health-related factors (Table 3) . Operable patients experienced a significantly increased overall survival compared with nonoperable patients at all stages of disease (p < 0.001, Table 3 ). A Cox proportional hazards model was developed to characterize independent predictors of survival in untreated NSCLC patients with operable disease (Table 4) . Male gender, increasing age, white (vs black) race, increasing comorbidity, squamous cell or large cell histology, and increasing stage were independently associated with decreased survival.
Comment
Lung cancer tends to occur in patients of an age and lifestyle (tobacco use) that puts them at risk for significant medical problems [14] . These medical problems may affect not only the safety of lung cancer resection but also the patient's survival in the absence of surgical resection. We hypothesized that patient health could also affect the natural history of NSCLC, which is an important perspective for patients as they consider lung cancer treatment. To test this hypothesis, we compared untreated patients who were recommended to undergo resection (operable) with untreated patients who were not recommended to undergo resection because of health-related reasons (nonoperable). Our analysis supports this hypothesis, indicating that survival was significantly improved for operable patients compared with nonoperable patients in the NCDB.
The findings in the current study extend those of previous attempts to characterize the natural history of NSCLC. More specifically, the reported 5-year survival for untreated early-stage NSCLC patients (including operable or nonoperable patients) has ranged from 2% to 14%, with some studies indicating worse overall survival among untreated patients with poorer performance status [7, 15] . The natural history of operable stage I NSCLC was specifically examined in a 2007 report from the California Tumor Registry. This study found untreated patients who refused a recommended operation had a better 5-year survival (11%) than the entire untreated cohort (6%) [16] . These previous reports support the current study findings that operable NSCLC patients can expect a modest survival advantage. There are some key differences between the current study and previous studies. First, the present study was able to fully characterize all treatment modalities that may have been used in the patient's first course of treatment (eg, resection, chemotherapy, radiotherapy, immunotherapy, hormonal therapy), whereas some previous studies were only able to exclude surgically treated patients. Furthermore, we excluded patients with bronchioalveolar carcinoma and adenocarcinoma in situ histology; therefore, a considerable strength of these data are that they likely reflect survival for true invasive disease by modern definitions [16] .
Our study has several limitations. Firstly, the NCDB does not specify who determines a patient's operability, and thus, we cannot tell whether this decision was made by a surgeon, a tumor board, or a nonsurgically trained member of the oncology team.
The tumor registry data in the NCDB only includes the first course treatment; thus, some patients we have classified as being untreated possibly received treatment (palliative or curative) at a later time that was not part of the first course of treatment.
The NCDB does not contain more detailed comorbidity or functional testing data (eg, lung function, functional status, etc) that would be relevant to determining a patient's ability to undergo an operation.
Finally, the NCDB does not provide cause of death; therefore, determining disease-specific survival is not possible. This could be an important aspect to study in the future, because we hypothesize the survival advantage observed in the "operable" cohort at least partly relates to better health.
This study provides a stage-specific estimate of the expected survival for operable NSCLC patients should they choose to go untreated. We believe that this perspective is a valuable addition to the risk-benefit deliberation as patients contemplate surgical management of locoregionally confined lung cancer. However, given that the patients included this study still likely are heterogeneous in ways that we are unable to completely characterize, we caution against applying these results in an exact quantitative manner to individual patients.
In conclusion, the natural history of patients with NSCLC is overall poor; however, patients with operable disease appear to have a better prognosis than those with nonoperable disease. To our knowledge, this is the first study to specifically examine the natural history of operable NSCLC in a national database. The data presented here can be used to help inform and guide patients to select appropriate treatment options. 
INVITED COMMENTARY
Rosen and colleagues [1] describe the natural history of treatable but untreated lung cancer in a cohort of patients from a large administrative database. The information presented is clinically useful and builds on prior findings from state registries. This study validates the long-held assumption that treatment for lung cancer does more good than harm. Although only surgery as treatment is addressed, the findings are likely equally applicable to nonoperative therapies such as stereotactic body radiotherapy. The data also retrospectively confirm that surgeons are generally making the appropriate decision when declining to operate on a certain cohort of patients with resectable cancer, with such untreated patients demonstrating much shorter median survival than untreated but operable patients.
Philosophically and clinically, the more difficult question to answer is "which patients should not be offered any treatment for early-stage lung cancer?" The gray zone of high-risk or marginally operable patients who should definitely receive nonoperative treatment remains highly subjective and contentious. At the extreme of this spectrum are medically inoperable patients. One may argue that a relatively low-risk strategy such as stereotactic body radiotherapy should be uniformly offered to all these patients. However, anecdotal evidence of serious harm after nonoperative treatments, the substantial cost, and lack of evidence of benefit with a short expected lifespan are significant concerns. Only prospective data can truly inform this difficult decision in a society and medical system that is geared toward "doing something" about every potentially treatable medical problem. Clinically and ethically it remains our responsibility to understand when a patient will likely die with lung cancer rather than from it.
Large databases like the National Cancer Database are excellent resources for understanding real-world treatment outcomes and to study general trends in disease presentation and management. They provide guidance when prospective, randomized trials are elusive. The National Cancer Database, like other administrative or claims databases, relies on professional coders to input patient-level data. When extracting information about an uncommon or rarely coded event like a patient declining surgery despite a surgeon recommendation for the same, one must take into account that this is not a billable event. The avidity with which a coder might be anticipated to extract and record such information would probably be less than the reliability of reporting an active billable intervention like surgery or chemotherapy. This may lead to underreporting of such events, which may in turn lead to variation in the precision of the results. Nevertheless, it does not change the direction of the findings, and the overall message from Rosen and colleagues [1] 
